Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Teva is looking to evolve its business through ... Purdue markets OxyContin, and is facing legal action alleging aggressive marketing of the drug from the 1990s helped create the problem.

We tested 24 winter boots for women from Baffin, Xero, Ugg and more, and three kept our toes toasty during the coldest months ...

States are channeling funds into overdose response equipment, drug identification tools and community recovery initiatives ...

Duvakitug hails from Teva’s labs, though Sanofi got in on the action last October when it laid out $500 million upfront to partner on development and marketing of the antibody. Under the deal ...

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

Teva Pharmaceutical Industries Limited (TEVA ... We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe ...

Teva Pharmaceutical is the leading generic drug ... Gear advertisements and other marketing efforts towards your interests. To learn more about how we handle and protect your data, visit our ...

Ten companies bucked an overall bearish market sentiment, booking significant gains during the last trading day of the week.

Under the deal, Teva’s Thailand outfit—which includes a team of about 80 workers—is set to become a wholly owned subsidiary of Lotus, which will take over the sales and marketing of existing ...